Ferroptosis: mechanisms and therapeutic targets

IF 10.7 Q1 MEDICINE, RESEARCH & EXPERIMENTAL
MedComm Pub Date : 2024-11-20 DOI:10.1002/mco2.70010
Qian Zhou, Yu Meng, Jiayuan Le, Yuming Sun, Yating Dian, Lei Yao, Yixiao Xiong, Furong Zeng, Xiang Chen, Guangtong Deng
{"title":"Ferroptosis: mechanisms and therapeutic targets","authors":"Qian Zhou,&nbsp;Yu Meng,&nbsp;Jiayuan Le,&nbsp;Yuming Sun,&nbsp;Yating Dian,&nbsp;Lei Yao,&nbsp;Yixiao Xiong,&nbsp;Furong Zeng,&nbsp;Xiang Chen,&nbsp;Guangtong Deng","doi":"10.1002/mco2.70010","DOIUrl":null,"url":null,"abstract":"<p>Ferroptosis is a nonapoptotic form of cell death characterized by iron-dependent lipid peroxidation in membrane phospholipids. Since its identification in 2012, extensive research has unveiled its involvement in the pathophysiology of numerous diseases, including cancers, neurodegenerative disorders, organ injuries, infectious diseases, autoimmune conditions, metabolic disorders, and skin diseases. Oxidizable lipids, overload iron, and compromised antioxidant systems are known as critical prerequisites for driving overwhelming lipid peroxidation, ultimately leading to plasma membrane rupture and ferroptotic cell death. However, the precise regulatory networks governing ferroptosis and ferroptosis-targeted therapy in these diseases remain largely undefined, hindering the development of pharmacological agonists and antagonists. In this review, we first elucidate core mechanisms of ferroptosis and summarize its epigenetic modifications (e.g., histone modifications, DNA methylation, noncoding RNAs, and N6-methyladenosine modification) and nonepigenetic modifications (e.g., genetic mutations, transcriptional regulation, and posttranslational modifications). We then discuss the association between ferroptosis and disease pathogenesis and explore therapeutic approaches for targeting ferroptosis. We also introduce potential clinical monitoring strategies for ferroptosis. Finally, we put forward several unresolved issues in which progress is needed to better understand ferroptosis. We hope this review will offer promise for the clinical application of ferroptosis-targeted therapies in the context of human health and disease.</p>","PeriodicalId":94133,"journal":{"name":"MedComm","volume":"5 12","pages":""},"PeriodicalIF":10.7000,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mco2.70010","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"MedComm","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/mco2.70010","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Ferroptosis is a nonapoptotic form of cell death characterized by iron-dependent lipid peroxidation in membrane phospholipids. Since its identification in 2012, extensive research has unveiled its involvement in the pathophysiology of numerous diseases, including cancers, neurodegenerative disorders, organ injuries, infectious diseases, autoimmune conditions, metabolic disorders, and skin diseases. Oxidizable lipids, overload iron, and compromised antioxidant systems are known as critical prerequisites for driving overwhelming lipid peroxidation, ultimately leading to plasma membrane rupture and ferroptotic cell death. However, the precise regulatory networks governing ferroptosis and ferroptosis-targeted therapy in these diseases remain largely undefined, hindering the development of pharmacological agonists and antagonists. In this review, we first elucidate core mechanisms of ferroptosis and summarize its epigenetic modifications (e.g., histone modifications, DNA methylation, noncoding RNAs, and N6-methyladenosine modification) and nonepigenetic modifications (e.g., genetic mutations, transcriptional regulation, and posttranslational modifications). We then discuss the association between ferroptosis and disease pathogenesis and explore therapeutic approaches for targeting ferroptosis. We also introduce potential clinical monitoring strategies for ferroptosis. Finally, we put forward several unresolved issues in which progress is needed to better understand ferroptosis. We hope this review will offer promise for the clinical application of ferroptosis-targeted therapies in the context of human health and disease.

铁蛋白沉积症:机制和治疗目标
铁凋亡是一种非凋亡性细胞死亡形式,其特征是膜磷脂中铁依赖性脂质过氧化。自 2012 年被发现以来,大量研究揭示了它与癌症、神经退行性疾病、器官损伤、传染病、自身免疫性疾病、代谢紊乱和皮肤病等多种疾病的病理生理学之间的关系。众所周知,可氧化脂质、过量铁和受损的抗氧化系统是导致脂质过氧化的关键先决条件,最终会导致质膜破裂和铁细胞死亡。然而,这些疾病中制约铁氧化和铁氧化靶向治疗的精确调控网络在很大程度上仍未确定,阻碍了药理激动剂和拮抗剂的开发。在这篇综述中,我们首先阐明了铁变性的核心机制,并总结了其表观遗传修饰(如组蛋白修饰、DNA 甲基化、非编码 RNA 和 N6-甲基腺苷修饰)和非表观遗传修饰(如基因突变、转录调控和翻译后修饰)。然后,我们讨论了铁蛋白沉积与疾病发病机制之间的关联,并探讨了针对铁蛋白沉积的治疗方法。我们还介绍了潜在的铁蛋白沉积症临床监测策略。最后,我们提出了几个尚未解决的问题,这些问题需要取得进展才能更好地理解铁蛋白沉积症。我们希望这篇综述能为人类健康和疾病方面的铁蛋白沉积症靶向疗法的临床应用带来希望。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.70
自引率
0.00%
发文量
0
审稿时长
10 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信